Meghan E. Shea, MD

Articles by Meghan E. Shea, MD

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilson Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Meghan E. Shea, MD, attending medical oncologist, ambulatory medical director, disease program leader for medical oncology, Beth Israel Deaconess Medical Center

Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

ByUrsula A. Matulonis, MD,Meghan E. Shea, MD

May 27th 2026

Drs Matulonis and Shea explore the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and ADCs across disease settings.

Meghan E. Shea, MD

Articles by Meghan E. Shea, MD

Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

Latest Updated Articles

Trending on OncLive

FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors

Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026

Phosphorus-32 Plus FOLFIRINOX Meets Primary End Points in Locally Advanced Pancreatic Cancer

FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer